Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Bottaro Website

Donald P. Bottaro, Ph.D.

Selected Publications

1)  Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
J. Clin. Oncol. 31: 181-6, 2013.
[Journal]
2)  Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS ONE. 8: e54014, 2013.
[Journal]
3)  Zhang M, Luo Z, Liu H, Croce CM, Burke TR, Bottaro DP.
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.
Leukemia. 2013.
[Journal]
4)  Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N.
Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.
PLoS ONE. 7: e42717, 2012.
[Journal]
5)  Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.
Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab.
J. Nucl. Med. 53: 1592-600, 2012.
[Journal]
6)  McKee TC, Rabe D, Bokesch HR, Grkovic T, Whitson EL, Diyabalanage T, Van Wyk AW, Marcum SR, Gardella RS, Gustafson KR, Linehan WM, McMahon JB, Bottaro DP.
Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.
J. Nat. Prod. 75: 1632-6, 2012.
[Journal]
7)  Cecchi F, Bottaro DP.
Novel antagonists of heparin binding growth factors.
Oncotarget. 3: 911-2, 2012.
[Journal]
8)  Cecchi F, Pajalunga D, Fowler CA, Uren A, Rabe DC, Peruzzi B, Macdonald NJ, Blackman DK, Stahl SJ, Byrd RA, Bottaro DP.
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling.
Cancer Cell. 22: 250-62, 2012.
[Journal]
9)  Cecchi F, Rabe DC, Bottaro DP.
Targeting the HGF/Met signaling pathway in cancer therapy.
Expert Opin. Ther. Targets. 16: 553-72, 2012.
[Journal]
10)  Bokesch HR, Gardella RS, Rabe DC, Bottaro DP, Linehan WM, McMahon JB, McKee TC.
A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum.
Chem. Pharm. Bull. 59: 1178-9, 2011.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 1/27/2014.